RxDoctor Payments DataLook up a doctor →

Dennis Duriex, MD

Infectious Disease · Lubbock, TXNPI 1336145838

Payments from drug & device makers

$407,854in general payments, 2019–2025

Across 410 payments — averaging $994.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Beigene, Ltd.$313K
  • Regeneron$87K
  • Viiv Healthcare Company$2K
  • Merck$1K
  • Gilead$832
  • AbbVie$775
  • plus $3K from 16 others

What the payments were for

  • Food & beverage$7,672100%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$407,854 in reported general payments places this provider in the 90th percentile of 576 infectious disease providers in Texas.

See all infectious disease providers in Texas

Medicare billing

Part B allowed, 2024
$183,823
Medicare patients
437
Services billed
1,979

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
DovatoDolutegravir Sodium/Lamivudine65$195,791
BiktarvyBictegrav/Emtricit/Tenofov Ala50$194,690
Egrifta SvTesamorelin Acetate11$80,212
Daptomycin120$65,534
TriumeqAbacavir/Dolutegravir/Lamivudi11$46,386
TeflaroCeftaroline Fosamil Acetate16$27,853
ErtapenemErtapenem Sodium55$19,397
Cefepime Hcl49$10,996
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam24$3,811
CeftriaxoneCeftriaxone Sodium72$3,148
Doxycycline Hyclate112$3,061
Meropenem13$2,831
Ceftazidime15$2,322
Sodium Chloride0.9 % Sodium Chloride112$889
Vancomycin Hcl14$766

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato, Triumeq$2,220$242,17776 claims
GileadBiktarvy$832$194,69050 claims
Theratechnologies Inc.Egrifta Sv$94$80,21211 claims
AbbVieTeflaro$775$27,85316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 576 infectious disease providers in Texas.

Other infectious disease in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →